Nothing Special   »   [go: up one dir, main page]

PL2131860T3 - Przeciwciała przeciwko sklerostynie - Google Patents

Przeciwciała przeciwko sklerostynie

Info

Publication number
PL2131860T3
PL2131860T3 PL08731905T PL08731905T PL2131860T3 PL 2131860 T3 PL2131860 T3 PL 2131860T3 PL 08731905 T PL08731905 T PL 08731905T PL 08731905 T PL08731905 T PL 08731905T PL 2131860 T3 PL2131860 T3 PL 2131860T3
Authority
PL
Poland
Prior art keywords
sclerostin antibodies
sclerostin
antibodies
Prior art date
Application number
PL08731905T
Other languages
English (en)
Inventor
Andrew Ihor Korytko
David Matthew Marquis
Eric Michael Smith
Barbara Anne Swanson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL2131860T3 publication Critical patent/PL2131860T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL08731905T 2007-03-20 2008-03-11 Przeciwciała przeciwko sklerostynie PL2131860T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89581307P 2007-03-20 2007-03-20
PCT/US2008/056527 WO2008115732A2 (en) 2007-03-20 2008-03-11 Anti-sclerostin antibodies
EP08731905.9A EP2131860B1 (en) 2007-03-20 2008-03-11 Anti-sclerostin antibodies

Publications (1)

Publication Number Publication Date
PL2131860T3 true PL2131860T3 (pl) 2014-05-30

Family

ID=39756356

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08731905T PL2131860T3 (pl) 2007-03-20 2008-03-11 Przeciwciała przeciwko sklerostynie

Country Status (32)

Country Link
US (3) US7744874B2 (pl)
EP (2) EP2664346A1 (pl)
JP (2) JP2010524846A (pl)
KR (1) KR101123487B1 (pl)
CN (1) CN101646457B (pl)
AU (1) AU2008229141B2 (pl)
BR (1) BRPI0809026A2 (pl)
CA (1) CA2682212C (pl)
CO (1) CO6230999A2 (pl)
CR (1) CR11004A (pl)
CY (1) CY1114784T1 (pl)
DK (1) DK2131860T3 (pl)
DO (1) DOP2009000223A (pl)
EA (1) EA018204B1 (pl)
EC (1) ECSP099658A (pl)
ES (1) ES2446293T3 (pl)
HK (1) HK1138790A1 (pl)
HR (1) HRP20140108T1 (pl)
IL (1) IL200437A0 (pl)
MA (1) MA31308B1 (pl)
MX (1) MX2009010051A (pl)
MY (1) MY149129A (pl)
NZ (1) NZ578870A (pl)
PL (1) PL2131860T3 (pl)
PT (1) PT2131860E (pl)
RS (1) RS53157B (pl)
SI (1) SI2131860T1 (pl)
SV (1) SV2009003374A (pl)
TN (1) TN2009000383A1 (pl)
UA (1) UA96474C2 (pl)
WO (1) WO2008115732A2 (pl)
ZA (1) ZA200906345B (pl)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552959A (en) 1998-11-27 2008-06-30 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
PT3345607T (pt) 2006-12-29 2022-11-21 Ossifi Mab Llc Métodos para alterar o crescimento ósseo por administração de antagonista ou agonista de sost ou wise
PL2131860T3 (pl) * 2007-03-20 2014-05-30 Lilly Co Eli Przeciwciała przeciwko sklerostynie
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
CN101896201A (zh) * 2007-12-14 2010-11-24 安进公司 使用抗硬骨素抗体治疗骨折的方法
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
BR112012025568A2 (pt) 2010-04-07 2017-03-28 Abbvie Inc proteínas de ligação ao tnf-<244>.
EP2558106A1 (en) 2010-04-16 2013-02-20 Novartis AG Methods and compositions for improving implant osseointegration
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2011159704A1 (en) * 2010-06-14 2011-12-22 Vaccinex, Inc. Anti-vegf antibodies and uses thereof
TWI616204B (zh) 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
JP5319651B2 (ja) * 2010-11-18 2013-10-16 日本電信電話株式会社 分析方法
WO2012073992A1 (ja) 2010-11-30 2012-06-07 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
CA2830538C (en) 2011-03-25 2020-05-12 Amgen Inc. Anti - sclerostin antibody crystals and formulations thereof
PL2699261T3 (pl) 2011-04-19 2018-12-31 Amgen Inc. Metoda leczenia osteoporozy
EP2702408A1 (en) 2011-04-29 2014-03-05 Novartis AG Methods of treating squamous cell carcinoma related applications
LT2739311T (lt) * 2011-08-04 2018-06-11 Amgen Inc. Kaulų tarpų defektų gydymo būdas
JP2014533659A (ja) 2011-10-24 2014-12-15 アッヴィ・インコーポレイテッド スクレロスチンに対するイムノバインダー
CN104185641A (zh) 2011-10-24 2014-12-03 艾伯维公司 针对tnf和il-17的双特异性免疫结合剂
PE20141545A1 (es) 2011-10-24 2014-11-26 Abbvie Inc Inmunoenlazadores dirigidos contra el tnf
CN107126560A (zh) 2011-12-28 2017-09-05 安进公司 通过使用抗骨硬化蛋白抗体治疗牙槽骨流失的方法
US9925260B2 (en) 2012-07-05 2018-03-27 Ucb Pharma S.A. Treatment for bone diseases
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US20140065144A1 (en) * 2012-08-30 2014-03-06 National Cheng Kung University Use of il-20 antagonists for promoting bone fracture healing
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
US9763911B2 (en) 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
MA41101A (fr) * 2014-12-03 2017-10-10 Lilly Co Eli Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP6850255B2 (ja) 2014-12-30 2021-03-31 セルジーン コーポレイション 抗−ｃｄ４７抗体及びその使用
EP3782641A1 (en) * 2015-03-13 2021-02-24 Jiangsu Hengrui Medicine Co., Ltd. Anti-sclerostin antibody, antigen binding fragment and medical use thereof
US10906987B2 (en) 2016-03-01 2021-02-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (PVR)
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
JP2019527710A (ja) 2016-08-08 2019-10-03 アムジエン・インコーポレーテツド 抗スクレロスチン抗体を用いた結合組織付着の改善方法
EA201990557A1 (ru) * 2016-10-28 2019-09-30 Эли Лилли Энд Компани Анти-rankl антитела и их применение
MA46724A (fr) * 2016-11-01 2021-04-21 Anaptysbio Inc Anticorps dirigés contre la mort programmée 1 (pd -1)
PT3478719T (pt) * 2016-12-21 2021-03-18 Mereo Biopharma 3 Ltd Uso de anticorpos anti-esclerostina no tratamento da osteogénese imperfeita
TWI767976B (zh) 2017-01-09 2022-06-21 美商提薩羅有限公司 用抗pd-1抗體治療癌症之方法
JP7191833B2 (ja) * 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
US11530240B2 (en) 2017-06-09 2022-12-20 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
AU2018305613A1 (en) * 2017-07-27 2020-01-30 Jiangsu Hengrui Medicine Co., Ltd. SOST antibody pharmaceutical composition and uses thereof
TWI842702B (zh) 2018-03-30 2024-05-21 美商安進公司 C末端抗體變體
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
AU2019316575A1 (en) 2018-08-10 2021-03-04 Amgen Inc. Method of preparing an antibody pharmaceutical formulation
CA3125033A1 (en) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
CN114630677A (zh) 2019-08-12 2022-06-14 安进公司 抗硬骨素抗体配制品
WO2025019728A1 (en) 2023-07-19 2025-01-23 Amgen Inc. Methods of buffer preparation for a therapeutic protein formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
NZ552959A (en) * 1998-11-27 2008-06-30 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
EP1366156A2 (en) 2000-06-19 2003-12-03 F. Hoffmann-La Roche Ag Osteolevin gene polymorphisms
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
AU2003283206A1 (en) * 2002-11-27 2004-06-18 Aventis Pharma Deutschland Gmbh A method and a system for establishing a quantity measure for joint destruction
EP1636270B1 (en) * 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
WO2005005604A2 (en) 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
US20090202986A1 (en) 2004-10-22 2009-08-13 Huse William D Methods of optimizing antibody variable region binding affinity
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP2097450A2 (en) 2006-11-10 2009-09-09 Amgen Inc. Antibody-based diagnostics and therapeutics
PL2131860T3 (pl) * 2007-03-20 2014-05-30 Lilly Co Eli Przeciwciała przeciwko sklerostynie

Also Published As

Publication number Publication date
US20090060924A1 (en) 2009-03-05
JP5758933B2 (ja) 2015-08-05
MY149129A (en) 2013-07-15
KR101123487B1 (ko) 2012-03-23
AU2008229141B2 (en) 2013-02-07
WO2008115732A2 (en) 2008-09-25
EP2131860A2 (en) 2009-12-16
CA2682212A1 (en) 2008-09-25
DOP2009000223A (es) 2009-10-15
CY1114784T1 (el) 2016-12-14
TN2009000383A1 (en) 2010-12-31
EA200970874A1 (ru) 2010-02-26
CN101646457B (zh) 2013-05-01
EP2664346A1 (en) 2013-11-20
CN101646457A (zh) 2010-02-10
WO2008115732A3 (en) 2008-12-11
JP2010524846A (ja) 2010-07-22
SV2009003374A (es) 2011-01-10
DK2131860T3 (da) 2014-01-13
RS53157B (en) 2014-06-30
EP2131860B1 (en) 2013-12-18
HRP20140108T1 (hr) 2014-02-28
US20110250205A1 (en) 2011-10-13
CO6230999A2 (es) 2010-12-20
SI2131860T1 (sl) 2014-02-28
US20100221263A1 (en) 2010-09-02
ZA200906345B (en) 2010-11-24
IL200437A0 (en) 2010-04-29
ES2446293T3 (es) 2014-03-07
AU2008229141A1 (en) 2008-09-25
CR11004A (es) 2009-11-02
NZ578870A (en) 2012-01-12
US8257704B2 (en) 2012-09-04
HK1138790A1 (en) 2010-09-03
KR20090114462A (ko) 2009-11-03
US7744874B2 (en) 2010-06-29
MX2009010051A (es) 2009-10-12
PT2131860E (pt) 2014-03-04
ECSP099658A (es) 2009-10-30
JP2013151504A (ja) 2013-08-08
US7988970B2 (en) 2011-08-02
EA018204B1 (ru) 2013-06-28
MA31308B1 (fr) 2010-04-01
CA2682212C (en) 2014-05-06
BRPI0809026A2 (pt) 2014-09-23
UA96474C2 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
IL200437A0 (en) Anti-sclerostin antibodies
PT2195026E (pt) Anticorpos anti-esclerostina
IL229512A (en) Anti-vegf antibodies
GB0708002D0 (en) Antibodies
SI2200700T1 (sl) Nova protitelesa
AP3371A (en) Anti-IGF antibodies
ZA201005348B (en) Humanized anti-c5ar antibodies
EP2331579A4 (en) MONOCLONAL ANTIBODIES
PL2146745T3 (pl) Pięcioswoiste przeciwciało
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
IL204835A0 (en) Humanized antibody
GB0821100D0 (en) Antibodies
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
GB0702888D0 (en) Novel Antibodies
GB0718737D0 (en) Antibodies
IL205073A0 (en) Anti-bst2 antibody
EP2160407A4 (en) NEUTRALIZING ANTIBODIES
IL207581A0 (en) Anti-tyrp1 antibodies
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
GB0724185D0 (en) Antibodies
GB0706965D0 (en) Humanized antibody
GB0706964D0 (en) Humanized antibody
GB0706963D0 (en) Humanized antibody
GB0823562D0 (en) Antibodies